CSL Behring begins rVIIa-FP Phase II / III trial for haemophilia A or B

Biopharmaceutical firm CSL Behring has started the Phase II / III clinical trial, which has been designed to assess the recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP or CSL689) to treat patients with congenital hae…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news